1 Min Read
FRANKFURT, Feb 28 (Reuters) - Denmark's Novo A/S has increased its holding in German biotech group Evotec AG to more than 10 percent, a regulatory filing showed on Tuesday.
Novo A/S, which controls Novo Nordisk, earlier this month acquired 8.9 percent of shares in Evotec via a capital increase.
As of Feb. 27, Novo A/S held 10.1 pct of shares in Evotec via investment vehicle Novo Nordisk Fonden, Tuesday's filing showed. (Reporting by Maria Sheahan; Editing by Victoria Bryan)